CORT Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$141.00median target· current $110.43 (+27.7%)4 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio251.96Forward 57.47
EPS (TTM)$0.4524.1% YoY
Profit margin6.6%HEALTHCARE
Market cap$12.26BLarge cap
Valuation
- Forward P/E
- 57.47
- PEG ratio
- 0.81
- P/B
- 17.36
- P/S (TTM)
- 14.75
- EV/EBITDA
- 1354.58
Profitability & growth
- ROE (TTM)
- 8.2%
- Operating margin
- 16.1%
- Revenue growth YoY
- 31.7%
- Dividend yield
- —
- Beta
- 0.46
Last earnings
Jul 29, 2026 · Estimate $-0.04 · Reported $0.36
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Corcept Therapeutics Incorporated
Company profileCorcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$12.26B
Shares outstanding$108.1M
52W high$126.38
52W low$28.66
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent